GENE ONLINE|News &
2026 Monthly Focus
[Illustrations] Selective Capital, Targeted Deals, and a Tightened Public-Market Bar: How 2026 Is Shaping M&A and IPOs
2026-02-09
[Illustrations] 2026 Policy and Geopolitics as Catalysts: IRA Pricing Mechanics and BIOSECURE’s Supply Chain Decoupling
2026-02-09
[Illustrations] Radiopharmaceuticals in 2026: Alpha Emitters, Industrial Scale, and the Supply Chain as Strategy
2026-02-09
[Illustrations] 2026 TechBio Stress Test: Can AI Deliver Real Drugs as Recursion, Insilico Medicine and Schrödinger Take Center Stage
2026-02-06
[Illustrations] 2026 Oncology Crossroads: Enhertu’s HER2 Tumor‑Agnostic Expansion, Front‑Line ADC Adoption, and the Clinical Proving Ground for Next‑Gen Mechanisms
2026-02-05
[Illustrations] 2026 Obesity’s Second Wave: Market Fragmentation Starts to Challenge First-Generation Dominance
2026-02-05
[Illustrations] 2026 Biopharma’s “Clearing Year”: IRA, BIOSECURE, and the Phase 3 Threshold Becoming the True Litmus Test
2026-02-05
Moderna and Recordati Form Strategic Alliance to Commercialize mRNA Therapy for Propionic Acidemia
2026-02-04
From CRISPR to National Security: How Rare Diseases Became America’s Next Strategic Industry
2026-02-03
Sanofi’s Venglustat Demonstrates Superiority Over ERT in Phase 3 Type 3 Gaucher Disease Trial
2026-02-02
LATEST
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
